PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
May 22, 2023 09:00 ET
|
PolyPid Ltd.
Recruitment to Resume Imminently Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, May 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a...
PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 10, 2023 07:00 ET
|
PolyPid Ltd.
Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections; Recruitment Expected to Resume Imminently Received...
PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023
April 26, 2023 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid to Participate in Upcoming Investor Conferences
April 24, 2023 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, April 24, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
April 14, 2023 16:01 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, April 14, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds
March 31, 2023 12:00 ET
|
PolyPid Ltd.
Company Also Restructures Existing Kreos Loan, Deferring Over $3 Million of Repayment PETACH TIKVA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the...
PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants
March 29, 2023 07:59 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced...
PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares
March 28, 2023 16:05 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, March 28, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced...
PolyPid to Present at the Barclays Global Healthcare Conference
March 07, 2023 08:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, March 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
February 08, 2023 07:00 ET
|
PolyPid Ltd.
Following Positive Communication with the FDA, Regulatory Pathway Clarified for D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections Company Expects to Resume Patient...